You are here

NOVEL CRF ANTAGONISTS FOR INFLAMMATION AND PAIN

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AR047739-01A1
Agency Tracking Number: AR047739
Amount: $130,048.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
NEUROCRINE BIOSCIENCES, INC. 10555 SCIENCE CENTER DR
SAN DIEGO, CA 92121
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARK LINDNER
 (858) 658-7618
 MLINDNER@NEUROCRINE.COM
Business Contact
 PAUL HAWRAN
Phone: (858) 658-7658
Email: PHAWRAN@NEUROCRINE.COM
Research Institution
N/A
Abstract

Inflammation and pain affect large and ever-increasing patient populations. Narcotics, corticosteroids, and NSAIDs are effective, but they are associated with tremendous adverse effects which now account for thousands of deaths each year. The long-term objective of this proposal is to develop a CRF receptor antagonist as an analgesic andanti-inflammatory agent with a novel mechanism of action, with equivalent anti-inflammatory and analgesic effects and an improved side-effect profile compared to currently available treatments. In preliminary experiments we have shown that tissue-resident mast cells in inflamed tissues have CRF receptors, and that CRF antagonists attenuate activation of these mast cells and produce robust analgesic effects. In Phase I, using rodent models of acute and chronic inflammation, we propose to determine if the analgesic effects of CRF antagonists can be attributed entirely to peripheral CRF-R1 receptors, if the analgesic and anti-inflammatory effects of CRF antagonists are detectable in chronic as well as acute inflammation, and if CRF antagonists are effective and have a low side-effect profile even after chronic administration. Phase II will focus on the medicinal chemistry, in vitro and in vivo biology needed to produce a small molecule CRF antagonist with optimal characteristics for the treatment of inflammatory disorders.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government